Ligochem Bio to present 'cancer cell guided missile' research in Europe
Translated from Korean, summarized and contextualized by DistantNews.
At a glance
News
Sources not specified
New plan
- Ligochem Bio is presenting research on two antibody-drug conjugate (ADC) candidates at the European Society for Medical Oncology (ESMO) congress.
- ESMO is considered one of the top three global cancer conferences.
- ADCs combine antibodies with drugs to precisely target cancer cells, earning them the nickname "guided missiles for cancer."
Ligochem Bio is set to present its latest research on two antibody-drug conjugate (ADC) candidates at the European Society for Medical Oncology (ESMO) congress. This prestigious event is recognized as one of the world's three leading cancer conferences, alongside the American Society of Clinical Oncology and the American Association for Cancer Research.
The company's work focuses on ADC technology, a cutting-edge approach that links antibodies with potent drugs. These engineered molecules are designed to specifically attack cancer cells while sparing healthy tissues, earning them the descriptive moniker of "guided missiles for cancer."
The presentation at ESMO underscores Ligochem Bio's commitment to advancing cancer treatment through innovative therapeutic strategies. The congress provides a vital platform for researchers and clinicians to share groundbreaking findings and foster collaboration in the fight against cancer.
DistantNews Editorial
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
